CareDx: Wells Fargo downgrades to Equal-Weight, PT to $14 from $19.
PorAinvest
viernes, 8 de agosto de 2025, 11:40 am ET1 min de lectura
CDNA--
CareDx reported earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago. The quarterly report represents an earnings surprise of -16.67%, indicating a significant drop from the previous year. However, it is important to note that this quarterly report includes non-recurring items.
Revenue for the quarter ended June 2025 was $86.68 million, which missed the Zacks Consensus Estimate by 4.45%. This compares to year-ago revenues of $92.27 million. Despite the revenue miss, the company has topped consensus revenue estimates two times over the last four quarters.
Wells Fargo cited several factors in its decision to downgrade the stock and reduce the price target. The investment bank noted that CareDx's earnings per share (EPS) missed expectations and that the company's revenue growth has slowed. Additionally, the firm cited concerns about the company's ability to maintain its growth trajectory in the face of increasing competition in the molecular diagnostics market.
Despite the downgrade, analysts remain optimistic about CareDx's long-term prospects. The company has shown a history of exceeding earnings expectations and has a strong pipeline of new products. Additionally, the company's recent acquisition of Cepheid has positioned it to expand its market share in the molecular diagnostics market.
Investors should closely monitor CareDx's earnings calls and future earnings expectations to gauge the company's performance and potential recovery. The sustainability of the stock's immediate price movement will largely depend on management's commentary on the earnings call.
References:
[1] https://www.nasdaq.com/articles/caredx-cdna-lags-q2-earnings-and-revenue-estimates
[2] https://www.investing.com/news/analyst-ratings/caredx-cdna-lags-q2-earnings-and-revenue-estimates
WFC--
CareDx: Wells Fargo downgrades to Equal-Weight, PT to $14 from $19.
Wells Fargo has downgraded its rating for CareDx (CDNA) to Equal-Weight and reduced its price target from $19.00 to $14.00. The investment bank's latest assessment comes after CareDx reported mixed earnings results for the second quarter of 2025. Despite the downgrade, the stock has shown resilience, with analysts noting the company's recent financial performance.CareDx reported earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago. The quarterly report represents an earnings surprise of -16.67%, indicating a significant drop from the previous year. However, it is important to note that this quarterly report includes non-recurring items.
Revenue for the quarter ended June 2025 was $86.68 million, which missed the Zacks Consensus Estimate by 4.45%. This compares to year-ago revenues of $92.27 million. Despite the revenue miss, the company has topped consensus revenue estimates two times over the last four quarters.
Wells Fargo cited several factors in its decision to downgrade the stock and reduce the price target. The investment bank noted that CareDx's earnings per share (EPS) missed expectations and that the company's revenue growth has slowed. Additionally, the firm cited concerns about the company's ability to maintain its growth trajectory in the face of increasing competition in the molecular diagnostics market.
Despite the downgrade, analysts remain optimistic about CareDx's long-term prospects. The company has shown a history of exceeding earnings expectations and has a strong pipeline of new products. Additionally, the company's recent acquisition of Cepheid has positioned it to expand its market share in the molecular diagnostics market.
Investors should closely monitor CareDx's earnings calls and future earnings expectations to gauge the company's performance and potential recovery. The sustainability of the stock's immediate price movement will largely depend on management's commentary on the earnings call.
References:
[1] https://www.nasdaq.com/articles/caredx-cdna-lags-q2-earnings-and-revenue-estimates
[2] https://www.investing.com/news/analyst-ratings/caredx-cdna-lags-q2-earnings-and-revenue-estimates
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios